The Relationship Between Endometrioma And Systemic Inflammation Indexes

Aim: Recent studies have examined systemic inflammatory markers like C-reactive protein (CRP) and fibrinogen, but the role of comprehensive indices such as the systemic immune inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune inflammation value (PIV) in endometrioma remains unclear. This study aimed to evaluate whether isolated endometrioma stimulates systemic inflammation by assessing SII, SIRI, and PIV. Material and Methods: A retrospective case-control study was conducted involving 213 patients with endometrioma and 207 controls with no gynecological or systemic diseases. Data collected included age, CA-125, CA 19-9, platelet, neutrophil, lymphocyte, monocyte counts, and inflammatory indices (SII, SIRI, PIV). Statistical analysis was performed using the Student’s t-test. Results: No significant differences were found between the endometrioma group and the control group in terms of SII (970±146.6 vs. 753±471, p=0.121), SIRI (1.73±1.21 vs. 1.39±1.02, p=0.107), or PIV (551±420 vs. 419±313, p=0.100). CA-125 and CA 19-9 levels were significantly higher in the endometrioma group compared to controls (p=0.003 and p=0.020, respectively). Conclusion: The study did not find significant evidence that isolated endometrioma induces systemic inflammation based on SII, SIRI, and PIV. The findings suggest that endometrioma may primarily cause localized inflammation rather than systemic effects. Limitations include the retrospective design and relatively small sample size, which may affect the generalizability and causality of the results. Further prospective studies with larger cohorts are needed to fully understand the systemic inflammatory implications of endometrioma.